DK3302483T3 - Farmaceutiske sammensætninger og anvendelse deraf - Google Patents

Farmaceutiske sammensætninger og anvendelse deraf Download PDF

Info

Publication number
DK3302483T3
DK3302483T3 DK16799287.4T DK16799287T DK3302483T3 DK 3302483 T3 DK3302483 T3 DK 3302483T3 DK 16799287 T DK16799287 T DK 16799287T DK 3302483 T3 DK3302483 T3 DK 3302483T3
Authority
DK
Denmark
Prior art keywords
application
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
DK16799287.4T
Other languages
English (en)
Inventor
Zhongzhou Liu
Chongdong Fu
Bin Shi
Original Assignee
Hutchison Medipharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchison Medipharma Ltd filed Critical Hutchison Medipharma Ltd
Application granted granted Critical
Publication of DK3302483T3 publication Critical patent/DK3302483T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK16799287.4T 2015-05-25 2016-05-24 Farmaceutiske sammensætninger og anvendelse deraf DK3302483T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2015/079650 WO2016187767A1 (en) 2015-05-25 2015-05-25 Pharmaceutical compositions and use thereof
PCT/CN2016/083098 WO2016188399A1 (en) 2015-05-25 2016-05-24 Pharmaceutical compositions and use thereof

Publications (1)

Publication Number Publication Date
DK3302483T3 true DK3302483T3 (da) 2020-06-15

Family

ID=57392304

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16799287.4T DK3302483T3 (da) 2015-05-25 2016-05-24 Farmaceutiske sammensætninger og anvendelse deraf

Country Status (26)

Country Link
US (1) US20180153890A1 (da)
EP (1) EP3302483B1 (da)
JP (1) JP6878309B2 (da)
KR (1) KR102573278B1 (da)
CN (1) CN107613984B (da)
AU (1) AU2016269304B2 (da)
BR (1) BR112017024126B8 (da)
CA (1) CA2985379C (da)
CY (1) CY1123408T1 (da)
DK (1) DK3302483T3 (da)
ES (1) ES2796575T3 (da)
HK (1) HK1245113A1 (da)
HR (1) HRP20200935T1 (da)
HU (1) HUE050697T2 (da)
LT (1) LT3302483T (da)
MX (1) MX2017014880A (da)
MY (1) MY188169A (da)
PH (1) PH12017502148A1 (da)
PL (1) PL3302483T3 (da)
PT (1) PT3302483T (da)
RS (1) RS60355B1 (da)
RU (1) RU2712187C2 (da)
SG (1) SG10202106375UA (da)
SI (1) SI3302483T1 (da)
TW (1) TWI714588B (da)
WO (2) WO2016187767A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7308145B2 (ja) 2016-11-18 2023-07-13 ハッチソン メディファーマ リミテッド 固形腫瘍を治療するための医薬組成物
CN111184698A (zh) * 2018-11-15 2020-05-22 和记黄埔医药（上海）有限公司 呋喹替尼制剂及其应用
CN114085214A (zh) * 2020-08-25 2022-02-25 和记黄埔医药（上海）有限公司 索凡替尼杂质及其制备方法和用途
US20220073642A1 (en) * 2020-09-07 2022-03-10 Hutchison Medipharma Limited Methods of using surufatinib in treating advanced pancreatic and extra-pancreatic neuroendocrine tumors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506783B1 (en) * 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
GB9914258D0 (en) * 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
US20040033267A1 (en) * 2002-03-20 2004-02-19 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
SG184755A1 (en) * 2004-03-15 2012-10-30 Ptc Therapeutics Inc Carboline derivatives useful in the inhibition of angiogenesis
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
JO2860B1 (en) * 2009-05-07 2015-03-15 ايلي ليلي اند كومباني Phenylendazolyl compounds
CN102070618B (zh) * 2009-11-23 2013-08-21 和记黄埔医药（上海）有限公司 一种化合物及其晶体
CN102775385A (zh) * 2011-05-10 2012-11-14 湖南有色凯铂生物药业有限公司 N-取代苯基-n’-取代杂环脲类化合物及其作为抗癌药物的应用

Also Published As

Publication number Publication date
TW201641108A (zh) 2016-12-01
PH12017502148A1 (en) 2018-05-28
CA2985379A1 (en) 2016-12-01
RS60355B1 (sr) 2020-07-31
EP3302483A1 (en) 2018-04-11
HK1245113A1 (zh) 2018-08-24
ES2796575T3 (es) 2020-11-27
BR112017024126B8 (pt) 2023-05-09
RU2017139880A (ru) 2019-06-25
HRP20200935T1 (hr) 2020-09-18
AU2016269304A1 (en) 2017-11-30
CA2985379C (en) 2023-08-01
MY188169A (en) 2021-11-24
BR112017024126B1 (pt) 2023-04-11
BR112017024126A2 (pt) 2018-07-31
LT3302483T (lt) 2020-06-25
SI3302483T1 (sl) 2020-07-31
AU2016269304B2 (en) 2021-04-15
PT3302483T (pt) 2020-06-16
JP6878309B2 (ja) 2021-05-26
WO2016188399A1 (en) 2016-12-01
TWI714588B (zh) 2021-01-01
US20180153890A1 (en) 2018-06-07
CN107613984A (zh) 2018-01-19
PL3302483T3 (pl) 2020-11-02
MX2017014880A (es) 2018-04-10
RU2017139880A3 (da) 2019-10-03
HUE050697T2 (hu) 2020-12-28
RU2712187C2 (ru) 2020-01-24
JP2018515587A (ja) 2018-06-14
KR102573278B1 (ko) 2023-09-01
SG10202106375UA (en) 2021-07-29
CN107613984B (zh) 2021-04-30
EP3302483B1 (en) 2020-04-15
KR20180006422A (ko) 2018-01-17
WO2016187767A1 (en) 2016-12-01
CY1123408T1 (el) 2021-12-31
EP3302483A4 (en) 2019-02-27
NZ737544A (en) 2021-06-25

Similar Documents

Publication Publication Date Title
DK3357513T3 (da) Farmaceutisk sammensætning og anvendelse deraf
DK3495023T3 (da) Semifluorerede forbindelser og sammensætninger deraf
DK3529248T3 (da) Farmaceutiske sammensætninger
DK3354282T3 (da) Glycan-terapeutiske midler og relaterede fremgangsmåder deraf
DK3018183T3 (da) Halogenolefinbaseret sammensætning og anvendelse deraf
DK3102200T3 (da) Terapeutisk forbindelse og sammensætning
MA41794A (fr) Agents thérapeutiques modifiés et compositions associées
DK3233111T3 (da) Farmaceutisk sammensætning, der omfatter plasminogen, og anvendelser deraf
DK3255042T3 (da) Heterocyklisk forbindelse og farmaceutisk sammensætning omfattende samme
DK3399978T3 (da) Antiproliferative forbindelser og farmaceutiske sammensætninger dermed og anvendelser deraf
DK3128005T3 (da) Sirp-alfa-variantkonstruktioner og anvendelser deraf
DK3223796T3 (da) Farmaceutiske sammensætninger, fremstilling og anvendelser deraf
DK3288379T3 (da) Peptidsammensætninger og anvendelsesmåder
DK3261609T3 (da) Sammensætninger omfattende ravsyre og akonitsyre
DK3583943T3 (da) Farmaceutisk sammensætning
DK3365321T3 (da) Solabegron-zwitterion og anvendelser deraf
DK3280405T3 (da) Inhibitorer og anvendelser deraf
DK3383397T3 (da) Farmaceutiske sammensætninger indeholdende doravirin, tenofovirdisoproxilfumarat og lamivudin
DK3388085T3 (da) Farmaceutisk sammensætning og anvendelser deraf
DK3386956T3 (da) Fumagillolderivater og polymorfer deraf
DK3321279T3 (da) Exenatidmodificeringsmiddel og anvendelse deraf
DK3328368T3 (da) Forbindelser og farmaceutisk sammensætning associeret med ubiquitinering-proteasomsystem
DK3229843T3 (da) Farmaceutisk sammensætning, præparat og anvendelser deraf
HK1245113A1 (zh) 藥物組合物及其用途
DK3236934T3 (da) Farmaceutisk sammensætning, fremstilling og anvendelser deraf